Natco Pharma Q2 FY27 revenue falls 30% as profit drops 61%
Key highlights
- Natco Pharma reported Q2 FY27 consolidated revenue of ₹1,019.4 crore, compared with ₹794 crore in Q1 FY27 and ₹1,463 crore a year earlier.
- Natco Pharma's Q2 FY27 profit after tax was ₹202.6 crore, down 60.9% year-on-year.
- Q2 FY27 EBITDA, including other income, was ₹310 crore and the EBITDA margin was 30.4%.
- Brazil revenue was ₹121 crore, up 66%, while domestic formulation revenue was ₹145 crore.
powered by IRIS

Natco Pharma Limited reported consolidated revenue of ₹1,019.4 crore in Q2 FY27, down 30.3% from ₹1,463 crore a year earlier, while profit after tax fell 60.9% year-on-year to ₹202.6 crore. The company attributed the annual decline mainly to lower lenalidomide revenue, although international formulations supported sequential revenue growth.
Know Natco Pharma inside out
Results, valuation, peers and who's buying, in one view.
What did Natco Pharma report for Q2 FY27?
Natco Pharma reported consolidated total revenue of ₹1,019.4 crore for the second quarter of FY27, compared with ₹794 crore in Q1 FY27 and ₹1,463 crore in Q2 FY26. This represented a sequential increase of ₹225.4 crore, while revenue was lower by ₹443.6 crore from the corresponding period a year earlier.
Consolidated profit after tax was ₹202.6 crore, compared with ₹206.5 crore in the preceding quarter. The company also reported EBITDA, including other income, of ₹310 crore, with an EBITDA margin of 30.4%. Revenue from operations was ₹967.3 crore and was down 29.0% year-on-year, according to the earnings-call summary.
Why did Natco Pharma's revenue decline year-on-year?
Natco Pharma said its year-on-year revenue decline was largely due to lower lenalidomide revenue during the quarter. Lenalidomide was specifically identified by management as the main reason consolidated revenue was below the prior-year level.
The company said growth in its base business, including subsidiaries, partly offset the decline in lenalidomide revenue. The transcript does not provide a separate revenue figure for lenalidomide or quantify the contribution from the base business. Therefore, the available disclosures establish the broad drivers of the annual comparison but do not provide a product-wise bridge for the revenue movement.
The quarterly comparison presented a different picture. Management said the increase from ₹794 crore in Q1 FY27 to ₹1,019.4 crore in Q2 FY27 was primarily driven by strong performance in international formulations. That sequential improvement supported a profit after tax of ₹202.6 crore, which was broadly close to the ₹206.5 crore reported in the previous quarter.
Got a follow-up? Ask IRIS
Which businesses supported Natco Pharma's quarterly performance?
Natco Pharma identified its international formulation business as the primary driver of the quarter-on-quarter revenue increase. The company also reported growth in Brazil, where revenue reached ₹121 crore, an increase of 66%.
Its domestic formulation business generated revenue of ₹145 crore in Q2 FY27. The earnings-call disclosures did not specify the comparable domestic revenue for the prior quarter or prior year, so the pace of change in the Indian formulations business cannot be calculated from the available information.
The company also provided an update on associate company Adcock Ingram Holding Limited in South Africa. Adcock Ingram reported quarterly revenue of ₹1,344 crore and profit after tax of ₹80.5 crore. Natco Pharma's share of profit, based on its 49% holding as of September 30, 2026 and after purchase price allocation adjustments, was ₹29.2 crore.
How does the Q2 FY27 performance matter for investors?
The Q2 results show that Natco Pharma's quarterly revenue improved from Q1 FY27, but remained materially below the level reported in Q2 FY26. The contrast reflects the importance of lenalidomide revenue in the previous-year comparison and the role of international formulations in supporting the latest quarter.
The 30.4% EBITDA margin and ₹310 crore EBITDA, including other income, indicate that the company remained profitable despite the lower annual revenue base. However, profit after tax of ₹202.6 crore was 60.9% lower year-on-year, as stated in the earnings-call summary, making the revenue mix and performance of non-lenalidomide businesses relevant to the financial comparison.
Brazil and the associate contribution from Adcock Ingram add geographic sources of earnings beyond domestic formulations. But the disclosed figures do not establish how these businesses will perform in later quarters. Investors have current-quarter data on Brazil, domestic formulations and Adcock Ingram, while product-level details on lenalidomide and other international formulations were not provided in the supplied transcript.
Conclusion
Natco Pharma's Q2 FY27 results combined a sequential recovery in consolidated revenue with a sharp year-on-year decline in revenue and profit. Consolidated revenue rose to ₹1,019.4 crore from ₹794 crore in Q1 FY27, supported by international formulations, but was below ₹1,463 crore in Q2 FY26 as lower lenalidomide revenue weighed on the comparison.
The next disclosures to watch are the performance of international formulations, Brazil and domestic formulations, alongside any further information on lenalidomide revenue. Management's reported figures of ₹121 crore in Brazil revenue, ₹145 crore in domestic formulation revenue and a ₹29.2 crore associate-profit share provide reference points for future quarterly comparisons.


